Skip to main content
Abbisko Cayman Limited logo

Abbisko Cayman Limited — Investor Relations & Filings

Ticker · 2256 ISIN · KYG0028A1085 LEI · 655600UAX2YV03PRXN31 HKEX Manufacturing
Open in API
Filings indexed 402 across all filing types
Latest filing 2025-06-18 Declaration of Voting R…
Country KY Cayman Islands
Listing HKEX 2256

About Abbisko Cayman Limited

http://www.abbisko.com

Abbisko Cayman Limited is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule therapies. The company leverages a robust in-house R&D engine and a multi-dimensional discovery platform to advance a rich pipeline focused primarily on oncology, encompassing both precision-oncology and immuno-oncology candidates. Key product candidates include pimicotinib, which has shown positive topline results for the treatment of tenosynovial giant cell tumor (TGCT). Abbisko aims to develop novel treatments that address critical unmet medical needs for patients globally.

Recent filings

Filing Released Lang Actions
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 18, 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an announcement of poll results from the company’s annual general meeting, listing the resolutions proposed at the AGM and the vote counts and percentages for each resolution. It does not itself present full financial statements or detailed strategic information; rather, it declares the voting outcomes. This matches the definition for Declaration of Voting Results & Voting Rights Announcements.
2025-06-18 English
Next Day Disclosure Returns
Transaction in Own Shares Classification · 1% confidence The document is a "Next Day Disclosure Return" under Hong Kong listing rules, detailing share repurchases, treasury share sales, changes in issued shares and related confirmations by the issuer. This is a company’s own share buyback and treasury share transaction report. It does not represent an earnings release, AGM materials, or annual/interim report, but specifically a report of the company buying back or selling its own shares. Therefore, it falls under Transaction in Own Shares (POS).
2025-06-17 English
VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS COMPLETES FIRST PATIENT DOSING IN REGISTRATIONAL STUDY OF IRPAGRATINIB FOR HCC
Regulatory Filings Classification · 1% confidence The document is a voluntary press release (“announcement”) regarding first patient dosing in a clinical trial by Abbisko Therapeutics. It does not present financial results (ER, IR), board or management changes (MANG), corporate actions (SHA, POS), or any other specific filing type listed. It is essentially a general corporate/business update. As such it falls into the fallback category “Regulatory Filings” (RNS).
2025-06-16 English
Next Day Disclosure Returns
Transaction in Own Shares Classification · 1% confidence The document is a Hong Kong Exchange “Next Day Disclosure Return” (Form FF305) detailing changes in issued shares and treasury shares, including a share repurchase report (Section II) with trading dates, number of shares repurchased, prices, aggregate amounts, and confirmations under the Main Board/GEM Rules. This is a regulatory report of the company buying back (and holding) its own shares. According to the category definitions, this corresponds to “Transaction in Own Shares” (POS).
2025-06-13 English
VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE FOUNDER, THE EXECUTIVE DIRECTOR, THE CHIEF EXECUTIVE OFFICER AND THE CHAIRMAN OF THE BOARD OF THE COMPANY AND UPDATES ON ON-MARK
Transaction in Own Shares Classification · 1% confidence The document is a voluntary announcement on HKEx regarding insider share purchases by the executive director/chairman and updates on the company’s on-market share repurchase plan. It reports the company’s repurchase of 8,695,000 shares under its plan (a share buyback) and thus clearly falls under “Transaction in Own Shares.”
2025-06-12 English
Next Day Disclosure Returns
Transaction in Own Shares Classification · 1% confidence The document is a Next Day Disclosure Return (Form FF305) required under HKEX Listing Rules, detailing changes in issued shares and treasury shares, including share repurchases and on-market sales of treasury shares. It specifically reports transactions in own shares (share buybacks and treasury share sales). This matches the "Transaction in Own Shares" category.
2025-06-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.